UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights

Belgian-based UCB SA UCBJF has agreed to buy Zogenix Inc ZGNX, a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy.

  • Investors will get $26 in cash for every Zogenix share, plus a potential $2 per share payment if Zogenix's Fintepla drug gets regulatory approval for Lennox-Gastaut syndrome by the end of 2023. 
  • The initial payment is 66% higher than Tuesday's closing price of $15.64.
  • Lennox-Gastaut syndrome is an orphan disease that causes seizures. 
  • Related: Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy.
  • Fintepla has already received regulatory approval in the U.S. and European Union for seizures caused by Dravet syndrome, a rare form of epilepsy.
  • UCB said it would finance the deal with cash and a new term loan. 
  • In addition to contributing to UCB's revenue growth after closing, the Zogenix deal is expected to be accretive to UCB's earnings from 2023 onwards.
  • Lazard and Barclays are UCB's financial advisors, while Bank of America Securities and SVB Leerink advised Zogenix.
  • Price Action: ZGNX shares surged 59.9% at $25.00 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasM&ANewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsepilepsywhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!